
REGISTERED NUMBER: SC356566 (Scotland)

Abbreviated Unaudited Accounts for the Year Ended 31 October 2011

for

3D Clinical Research Limited





3D Clinical Research Limited

Company Information for the Year Ended 31 October 2011

DIRECTORS:

Dr A Waddell Mrs F Waddell

SECRETARY:

Dr A Waddell

REGISTERED OFFICE:

18E Liberton Brae

Edinburgh Lothian EH16 6AE

REGISTERED NUMBER:

SC356566 (Scotland)

ACCOUNTANTS:

Brown, Scott & Main Chartered Accountants

91 West Savile Terrace

Edinburgh EH9 3DP

BANKERS:

Bank of Scotland

300 Lawnmarket

Edinburgh EH1 2PH 3D Clinical Research Limited (Registered number: SC356566)

Abbreviated Balance Sheet

31 October 2011

		2011	2010
	Notes	£	£
FIXED ASSETS	_		
Tangible assets	2	300	-
CURRENT ASSETS			
Debtors		7,059	23,719
Cash at bank and in hand		5,109	1,817
			
		12,168	25,536
CREDITORS			
Amounts falling due within one y	ear	(5,354)	(8,788)
NET OF DENIE ACCEPTS			16.740
NET CURRENT ASSETS		6,814	16,748
TOTAL ASSETS LESS CURR	FNT		
LIABILITIES		7,114	16,748
		,,	
CREDITORS			
Amounts falling due after more th	nan one		
year		(50,000)	(50,000)
NIDO A A DECEMBER		(42.096)	(22.252)
NET LIABILITIES		(42,886) ————	(33,252)
CAPITAL AND RESERVES			
Called up share capital	3	1	1
Profit and loss account		(42,887)	(33,253)
			
SHAREHOLDERS' FUNDS		(42,886)	(33,252)
			===

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 October 2011.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 October 2011 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The abbreviated accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial/statements were approved by the Board of Directors on 25 July 2012 and were signed on its behalf by:

Dr A Waddell - Director

The notes form part of these abbreviated accounts

3D Clinical Research Limited (Registered number: SC356566)

Notes to the Abbreviated Accounts for the Year Ended 31 October 2011

1. ACCOUNTING POLICIES

Accounting convention

The financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

Preparation of consolidated financial statements

The company is a member of a small group whose parent, Tower Mains Limited, has taken the option available under Section 398 of the Companies Act 2006 not to prepare consolidated financial statements.

Turnover

Turnover represents the total value, excluding value added tax, of revenue earned and client expenses recovered during the year from clinical trials consultancy, management and training services. Turnover recognised in advance of the client being billed is included in debtors under "accrued income".

Tangible fixed assets

Tangible fixed assets are stated at cost less accumulated depreciation. Depreciation is provided at rates calculated to write off the cost less residual value of each asset over its expected useful life as follows:

Office equipment

25% per annum straight line

Deferred tax

Deferred tax arises from including items of income and expenditure in taxation computations in periods different from those in which they are included in the company's financial statements. Deferred tax is provided on all temporary timing differences that have originated but not reversed by the balance sheet date. Deferred tax assets are recognised to the extent that it is probable that future taxable profit will be available against which any asset can be utilised. Deferred tax assets and liabilities are not discounted.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs

The pension costs charged in the financial statements represent the contributions payable by the company to a defined contribution pension scheme whose assets are held and managed separately by an independent company for the benefit of one of the directors. At the year end no contributions were outstanding to the pension scheme.

Group relief

Tax losses surrendered to any group company are paid in full by the claimant company.

Going concern

The financial statements are prepared on the going concern basis. The directors consider this remains appropriate as the company is able to meet its day to day working capital requirements as they fall due and expect it to be able to continue to do so for the foreseeable future with their continuing support as well as that of the holding company, Tower Mains Limited.

3D Clinical Research Limited (Registered number: SC356566)

Notes to the Abbreviated Accounts - continued for the Year Ended 31 October 2011

2. TANGIBLE FIXED ASSETS

					Total £
COST					~
Additions					327
At 31 Octob	er 2011				327
DEPRECIA	TION				
Charge for y	ear				27
At 31 October	er 2011				27
NET BOOK	VALUE				
At 31 October	er 2011				300
CALLED U	P SHARE CAPITA	AL .			
	ed and fully paid:				
Number:	Class:		Nominal value:	2011 £	2010 £
1,000	Ordinary		£1	1	1

4. ULTIMATE PARENT COMPANY

3.

The immediate and ultimate parent company is Tower Mains Limited.